Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 18;14(1):148-159.
doi: 10.18240/ijo.2021.01.21. eCollection 2021.

Sustained-release drug delivery systems for the treatment of glaucoma

Natasha P Kesav  1 , Cara E Capitena Young  2 , Monica K Ertel  2 , Leonard K Seibold  2 , Malik Y Kahook  2
Affiliations
Review

Sustained-release drug delivery systems for the treatment of glaucoma

Natasha P Kesav et al. Int J Ophthalmol. .

Abstract

Glaucoma, a leading cause of irreversible blindness, affects more than 64 million people worldwide and is expected to grow in number due to the aging global population and enhanced methods of detection. Although topical therapies are often effective when used as prescribed, the drawbacks of current medical management methods include poor patient adherence, local and systemic side effects, and in some cases, limited therapeutic efficacy. Novel ocular drug delivery platforms promise to deliver differentiated drug formulations with targeted delivery leveraging patient-independent administration. Several platforms are in various stages of development with promising pre-clinical and clinical data. The Bimatoprost Sustained Release (SR) intracameral implant was approved in the United States in March of 2020, making it the first long-term injectable therapy available for the treatment of glaucoma. This review aims to provide an update on novel sustained release drug delivery systems that are available today as well as those that might be commercialized in coming years.

Keywords: drug delivery; glaucoma; sustained release.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and Meta-analysis. Ophthalmology. 2014;121(11):2081–2090. - PubMed
    1. Quigley HA. 21st century glaucoma care. Eye (Lond) 2019;33(2):254–260. - PMC - PubMed
    1. Khaw PT, Shah P, Elkington AR. Glaucoma—2: treatment. BMJ. 2004;328(7432):156–158. - PMC - PubMed
    1. Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112(6):953–961. - PubMed
    1. Joseph A, Pasquale LR. Attributes associated with adherence to glaucoma medical therapy and its effects on glaucoma outcomes: an evidence-based review and potential strategies to improve adherence. Semin Ophthalmol. 2017;32(1):86–90. - PubMed

LinkOut - more resources